Clinical Trials · NCT00432172
Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Spanish Breast Cancer Research Group
- Enrollment
- 189
- Start date
- Apr 2007
- Locations
- 12 sites, Spain
- Primary endpoint
- Pathological Response for Basal Group 2